Navigation Links
'Synthetic lethality' strategy improves molecularly targeted cancer therapy
Date:9/21/2010

PHILADELPHIA (September 21, 2010)Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill thembut only if it was the right second agent.

One well-validated molecular target for anti-cancer drugs is the epidermal growth factor receptor, or EGFR. Using a novel screening approach, investigators in the Fox Chase Developmental Therapeutics Program identified over 60 additional proteins that are necessary for cells to survive in the presence of an EGFR inhibitor. When they simultaneously blocked the EGFR inhibitors and any one of these other proteins, more of the cancer cells died. The researchers say this screening strategy to identify targets for effective combinations of cancer drugs will open the door for future therapies. Already, two clinical trials are under way to test innovative drug combinations suggested by the new tactic.

"We found that knocking out one or the other target doesn't have a major effect, but knocking out both increases tumor cell death," says Igor Astsaturov, M.D., Ph.D., an assistant professor and medical oncologist at Fox Chase. Astsaturov led the study, which will be published in the September 21, 2010 issue of Science Signaling.

To identify additional targets that would boost the effectiveness of EGFR inhibitors against cancer, Astsaturov and colleagues screened only proteins that interact directly or indirectly with EGFR. The team mined the literature and built a candidate set of 638 EGFR-interacting proteins. They then used an experimental technique called small inhibitory RNA (siRNA) systematically to block activity of each of the genes in cancer cells that had been treated with an EGFR inhibitor. In doing so, the investigators demonstrated on three clinically relevant examples for which drugs are already availablePRKC, STAT3, and Aurora kinase Athat these proteins were necessary for cell survival in the presence of an EGFR inhibitor.

This two-hit strategywhere neither hit is adequate to kill the cells, but together they areis called synthetic lethality. Geneticists have used synthetic lethal screens in experiments with model organisms, such as fruit flies and yeast, for decades, but cancer researchers have only recently adopted the approach.

"We knew from model organisms that there was a dense network of genes. Using bioinformatics tools to intelligently mine this network provided us with a rich source of hits," says Erica A Golemis, Ph.D., professor and co-leader of the Developmental Therapeutics Program at Fox Chase, and senior author on the new study. Golemis is also co-leader of the Keystone Initiative in Head and Neck Cancer at Fox Chase, and notes that EGFR inhibitors are already broadly used in the clinic for cancers affecting the head and neck.

"The most exciting hit is the Aurora kinase," Golemis says. Several Aurora kinase inhibitors are already being tested in the clinic and thus are available for testing in combination with EGFR inhibitors.

Based on the new data, Hossein Borghaei, D.O., director of the Lung Cancer Risk Assessment Program at Fox Chase is launching a trial testing the EGFR inhibitor erlotinib with an Aurora kinase inhibitor in patients with non-small cell lung cancer. Astsaturov has started testing a drug called vandetanibwhich simultaneously inhibits EGFR and RET (another protein in the EGFR-interacting network)in patients with esophageal cancer.

In addition to providing a rich source of synthetic lethal hits, limiting the siRNA screen to a previously-defined network of interacting proteins had an important impact on the size of the project, according to Golemis. "A full genome siRNA screen is prohibitively expensive for many labs. This approach makes siRNA screens more accessible to smaller labs and academic institutions."


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Biosynthetic Corneas Show Promise in Transplants
2. Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children
3. Synthetic eye prosthesis
4. Chemo Plus Synthetic Drug Shrunk Pancreatic Tumors
5. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
6. Strategy discovered to prevent Alzheimers-associated traffic jams in the brain
7. Radiologists call for national strategy to address medical imaging overuse
8. HIV care providers and researchers applaud release of national HIV/AIDS strategy
9. HIV prevention strategy key to curbing epidemic and cutting long-term treatment costs
10. Larry Watkins Joins QualEDIx as Executive Vice President, Healthcare Strategy and Business Development
11. Internists outline comprehensive federal strategy to control tobacco use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... category by itself - the Vector™ Series Multi-Cook Oven offers up to four ... chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam has ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has a ... every household and family to know all about it for optimal health. Wanting to ... release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press AU). ...
(Date:2/21/2017)... ... February 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... be the keynote speaker at its second Professional Networking Breakfast on March 9, ... develops comprehensive strategies to create and expand opportunities for boys and young men ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals ... problems directly related to surgery, treatment, therapy and management. Regular exercise in proper ... qualities of life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017  Aytu BioScience, Inc. ... commercialization of novel products in the field of urology, ... to up to 42 account managers from 35 currently, ... The sales force expansion is being driven ... and revenues, an indication of increasing acceptance of Natesto,s ...
(Date:2/22/2017)... , Feb. 22, 2017  CVS Pharmacy is the ... of partially hydrogenated oils (PHO), the primary source of ... exclusive store brands food products. The retailer now offers ... free from artificial trans fats. This comes a year and ... deadline of June 2018 for processed foods to be ...
(Date:2/22/2017)... , Feb 22, 2017 Nordic Nanovector ... commercialisation of novel targeted therapeutics for haematological cancers, will announce its ... February 2017. ... presentation by Nordic Nanovector,s senior management team will take place at ... 45, 0250 Oslo Meeting Room: NYLAND The presentation will ...
Breaking Medicine Technology: